Bristol's Opdivo Enjoys IO First-Mover Advantage In Small Cell Lung Cancer
Executive Summary
In addition to Opdivo, three other PD-1/L1 inhibitors are in late-stage development for a high-unmet need disease, including Roche's Tecentriq, which will be filed as soon as possible.
You may also be interested in...
Merck & Co's Keytruda Disappoints In Small-Cell Lung Cancer
In top-line final Phase III results from KEYNOTE-604, Keytruda improves PFS but not OS when combined with chemotherapy for the first-line treatment of small-cell lung cancer.
Bristol’s Checkmate-331 Failure Not Likely To Endanger SCLC Labeling For Opdivo
Opdivo failed to meet an overall survival endpoint in a Phase III confirmatory study in small-cell lung cancer. But several analysts think Bristol will keep the SCLC labeling obtained in August due to lack of treatment options for these patients.
Tecentriq's Small-Cell Lung Cancer Success Takes Edge Off Roche's IO Position
Roche's combination of Tecentriq with chemotherapy is ahead of rivals in first-line SCLC and has been filed with the US FDA.